Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its pipeline includes bosakitug (ATI-045), an anti-TSLP monoclonal antibody for atopic dermatitis; ATI-2138, an oral covalent ITK/JAK3 dual inhibitor; ATI-052, an anti-TSLP/anti-IL-4Ra bispecific antibody; and ATI-9494, a JAK-sparing ITK inhibitor. The company uses its proprietary KINect drug discovery platform and seeks third-party partnerships for further development and commercialization.
Q2 FY2026 — expected 2026-08-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001104659-26-020540 | EDGAR | 88K words |
| 2025-02-27 | 2024-12-31 | 0001558370-25-001819 | EDGAR | 92K words |
| 2024-02-27 | 2023-12-31 | 0001558370-24-001753 | EDGAR | 76K words |
| 2023-02-23 | 2022-12-31 | 0001558370-23-001829 | EDGAR | 74K words |
| 2022-02-24 | 2021-12-31 | 0001558370-22-001838 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001558370-21-001717 | EDGAR | — |
| 2020-02-25 | 2019-12-31 | 0001558370-20-001325 | EDGAR | — |
| 2019-03-18 | 2018-12-31 | 0001558370-19-002211 | EDGAR | — |
| 2018-03-12 | 2017-12-31 | 0001558370-18-001866 | EDGAR | — |
| 2017-03-15 | 2016-12-31 | 0001558370-17-001802 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001104659-26-092065 | EDGAR | 22K words |
| 2025-11-06 | 2025-09-30 | 0001104659-25-107788 | EDGAR | 24K words |
| 2025-08-07 | 2025-06-30 | 0001558370-25-010789 | EDGAR | 24K words |
| 2025-05-08 | 2025-03-31 | 0001558370-25-006993 | EDGAR | 21K words |
| 2024-11-06 | 2024-09-30 | 0001558370-24-014646 | EDGAR | 23K words |
| 2024-08-07 | 2024-06-30 | 0001558370-24-011376 | EDGAR | 23K words |
| 2024-05-07 | 2024-03-31 | 0001558370-24-007069 | EDGAR | 20K words |
| 2023-11-06 | 2023-09-30 | 0001558370-23-017660 | EDGAR | 24K words |
| 2023-08-07 | 2023-06-30 | 0001558370-23-013491 | EDGAR | 23K words |
| 2023-05-08 | 2023-03-31 | 0001558370-23-008382 | EDGAR | 20K words |
| 2022-11-08 | 2022-09-30 | 0001558370-22-016738 | EDGAR | — |
| 2022-08-03 | 2022-06-30 | 0001558370-22-011757 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001104659-26-091629 | EDGAR | 3K words |
| 2026-08-06 | 0001104659-26-092128 | EDGAR | 22K words |
| 2026-03-11 | 0001104659-26-026407 | EDGAR | 1K words |
| 2026-03-10 | 0001104659-26-025420 | EDGAR | 1K words |
| 2026-02-26 | 0001104659-26-020070 | EDGAR | 3K words |
| 2026-01-12 | 0001104659-26-002694 | EDGAR | 7K words |
| 2026-01-06 | 0001104659-26-001076 | EDGAR | 3K words |
| 2025-11-06 | 0001104659-25-107353 | EDGAR | 3K words |
| 2025-10-14 | 0001104659-25-098991 | EDGAR | 11K words |
| 2025-08-07 | 0001558370-25-010640 | EDGAR | 3K words |
228 total filings indexed. 196 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001557746 |
| Ticker | ACRS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.aclaristx.com |
| Listed | 2015-10-07 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ACRS (~200 tokens, structured JSON with cryptographic provenance)